The landscape of drug discovery in atherosclerosis and dyslipidaemia revisited: An update of patenting activity

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 3, 2012, Pages 199-204

  Suckling, Keith ^a  

^a Suckling Science Ltd   (United Kingdom)

Author keywords

Atherosclerosis; Drug target; Dyslipidaemia; Inflammation; Metabolic syndrome

Indexed keywords

NICOTINAMIDE; PIOGLITAZONE; ROSIGLITAZONE; TORCETRAPIB;

ATHEROSCLEROSIS; DRUG TARGETING; DYSLIPIDEMIA; INFLAMMATION; METABOLIC SYNDROME X; PATENT; REVIEW; TREND STUDY;

ANIMALS; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; DYSLIPIDEMIAS; EUROPE; HUMANS; PATENTS AS TOPIC;

EID: 84858689428     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.667402     Document Type: Review

References (60)

1. Suckling K. The landscape of drug discovery in atherosclerosis and dyslipidaemia: a survey from patenting activity. Expert Opin Ther Patents 2008;18:473-84 (Pubitemid 351772541)
2. European Patent Office. Available from: http://www.epo.org/searching/ free/ espacenet.html
3. Federsel HJ. How to conduct research in the pharmaceutical industry? Facing the dilemma: small, autonomous teams versus large, integrated centers. Expert Opin Drug Discov 2010;5:813-18
4. Goodman M. Pharmaceutical industry financial performance. Nat Rev Drug Discov 2009;8:927-8
5. Garnier JP. Rebuilding the R&D engine in big pharma. Harv Bus Rev 2008;86:128
6. Plump A. Accelerating the pulse of cardiovascular R&D. Nat Rev Drug Discov 2010;9:823-4
7. Topol EJ. Past the wall in cardiovascular R&D. Nat Rev Drug Discov 2009;8:259
8. Suckling K. What is the future for drug development in atherosclerosis and dyslipidaemia? Expert Opin Drug Discov 2009;4:1-3
9. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317-25
10. King A. Coronary heart disease: new hope for CETP inhibitors. Nat Rev Cardiol 2011;8:5
11. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with orat high risk for coronary heart disease. N Engl J Med 2010;363:2406-15
12. Robinson JG. Dalcetrapib: a review of phase II data. Expert Opin Investig Drugs 2010;19:795-805
13. Rosenson RS. Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes. Curr Opin Lipidol 2010;21:47-80
14. Suckling K. Phospholipase A2s: developing drug targets for atherosclerosis. Atherosclerosis 2010;212:357-66
15. Maskrey BH, Megson IL, Whitfield PD, Rossi AG. Mechanisms of resolution of inflammation: a focus on Cardiovascular disease. Arterioscler Thromb Vasc Biol 2011;31:1001-6
16. Little PJ, Chait A, Bobik A. Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis. Pharmacol Ther 2011;131:255-68
17. Nissen SE. Atherosclerosis in 2010: new therapeutic insights. Nat Rev Cardiol 2011;8:70-2
18. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113-32
19. Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008;371:1927-35
20. Suckling K. Drug discovery in the metabolic syndrome: context and some recent developments. Expert Opin Ther Targets 2007;11:801-8 (Pubitemid 46901397)
21. Downey M, Still C, Sharma AM. Is there a path for approval of an antiobesity drug: what did the sibutramine cardiovascular outcomes trial find? Curr Opin Endocrinol Diabetes Obes 2011;18:321-7
22. Regulatory watch: FDA issues guidance for cardiovascular risk assessment of novel antidiabetic agents. Nat Rev Drug Discov 2009;8:99
23. DeSouza C, Fonseca V. Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nat Rev Drug Discov 2009;8:361-7
24. Zhao L, Jin W, Rader D, et al. A Translational Medicine perspective of the development of torcetrapib: does the failure of torcetrapib development cast shadow on future development of lipid modifying agents HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and translational medicine in atherosclerosis drug discovery and development. Biochem Pharmacol 2009;78:315-25
25. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-201
26. Pioglitazone: risk of bladder cancer. WHO Drug Info 2011;25:243
27. Lalloyer F, Staels B. Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 2010;30:894-9
28. Jones D. Potential remains for PPAR-targeted drugs. Nat Rev Drug Discov 2010;9:668-9
29. Karpe F, Ehrenborg EE. PPARdelta in humans: genetic and pharmacological evidence for a significant metabolic function. Curr Opin Lipidol 2009;20:333-6
30. Im SS, Osborne TF. Liver X receptors in atherosclerosis and inflammation. Circ Res 2011;108:996-1001
31. Calkin AC, Tontonoz P. Liver X receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol 2010;30:1513-18
32. Briand F, Treguier M, Andre A, et al. Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. J Lipid Res 2010;51:763-70
33. Zammit VA, Buckett LK, Turnbull AV, et al. Diacylglycerol acyltransferases: potential roles as pharmacological targets. Pharmacol Ther 2008;118:295-302
34. Lampidonis AD, Rogdakis E, Voutsinas GE, Stravopodis DJ. The resurgence of Hormone-Sensitive Lipase (HSL) in mammalian lipolysis. Gene 2011;477:1-11
35. DeWire SM, Violin JD. Biased ligands for better cardiovascular drugs. Circ Res 2011;109:205-16
36. Talukdar S, Olefsky JM, Osborn O. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol Sci 2011;32:543-50
37. Boyle CD, Kowalski TJ. 11betahydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents. Expert Opin Ther Patents 2009;19:801-25
38. Wanders D, Judd RL. Future of GPR109A agonists in the treatment of dyslipidaemia. Diabetes Obes Metab 2011;13:685-91
39. Tao R, Wei D, Gao H, et al. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J Biol Chem 2011;286:14681-90
40. Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis 2011;216:258-65
41. Visser ME, Kastelein JJ, Stroes ES. Apolipoprotein B synthesis inhibition: results from clinical trials. Curr Opin Lipidol 2010;21:319-23
42. Libby P, Ridker PM, Hansson GK; for the Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-38
43. Soro-Paavonen A, Watson AMD, Li J, et al. Receptor for AdVanced Glycation End Products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008;57:2461-9
44. Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci 2011;32:167-73
45. Loirand G, Pacaud P. The role of Rho protein signaling in hypertension. Nat Rev Cardiol 2010;7:637-47
46. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005;85:1-31 (Pubitemid 40171256)
47. Johnson JL, Devel L, Czarny B, et al. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-Knockout mice. Arterioscler Thromb Vasc Biol 2011;31:528-35
48. Johnson JL, Baker AH, Oka K, et al. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of Metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation 2006;113:2435-44 (Pubitemid 43948051)
49. Sukhova GK, Zhang Y, Pan JH, et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003;111:897-906 (Pubitemid 37074965)
50. Donners MMPC, Wolfs IMJ, Olieslagers S, et al. A disintegrin and metalloprotease 10 is a novel mediator of vascular endothelial growth factor-induced endothelial cell function in angiogenesis and is associated with atherosclerosis. Arterioscler Thromb Vasc Biol 2010;30:2188-95
51. Johnson JL, Dwivedi A, Somerville M, et al. Matrix metalloproteinase (MMP)- 3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler Thromb Vasc Biol 2011;31:e35-44
52. Tarin C, Gomez M, Calvo E, et al. Endothelial nitric oxide deficiency reduces MMP-13-Mediated cleavage of ICAM-1 in vascular endothelium: a role in atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:27-32
53. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011;31:986-1000
54. Cipollone F, Cicolini G, Bucci M. Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther 2008;118:161-80
55. Shen HC. Soluble epoxide hydrolase inhibitors: a patent review. Expert Opin Ther Patents 2010;20:941-56
56. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009;8:794-805
57. Linton MF, Fazio S. Cyclooxygenase products and atherosclerosis. Drug Discov Today 2008;5:25-36
58. Imai H, Numaguchi Y, Ishii M, et al. Prostacyclin synthase gene transfer inhibits neointimal formation by suppressing PPAR delta expression. Atherosclerosis 2007;195:322-32 (Pubitemid 350087962)
59. Tsai MC, Chen L, Zhou J, et al. Shear stress induces synthetic-to- contractile phenotypic modulation in smooth muscle cells via peroxisome proliferator-activated receptor {alpha}/ {delta} activations by prostacyclin released by sheared endothelial cells. Circ Res 2009;105:471-80
60. Alexopoulos N, Raggi P. Biomarkers: coronary artery calcium is a better risk marker than hsCRP. Nat Rev Cardiol 2011;8:616-18